Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Stock analysts at SunTrust Banks increased their Q4 2017 earnings per share estimates for shares of Supernus Pharmaceuticals in a research report issued to clients and investors on Wednesday. SunTrust Banks analyst J. Boris now forecasts that the specialty pharmaceutical company will post earnings of $0.29 per share for the quarter, up from their prior estimate of $0.24. SunTrust Banks has a “Buy” rating and a $61.00 price objective on the stock. SunTrust Banks also issued estimates for Supernus Pharmaceuticals’ FY2018 earnings at $1.56 EPS, FY2019 earnings at $2.32 EPS, FY2020 earnings at $3.34 EPS and FY2021 earnings at $4.84 EPS.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company’s revenue for the quarter was up 41.5% on a year-over-year basis. COPYRIGHT VIOLATION NOTICE: “Equities Analysts Offer Predictions for Supernus Pharmaceuticals, Inc.’s Q4 2017 Earnings (SUPN)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/equities-analysts-offer-predictions-for-supernus-pharmaceuticals-inc-s-q4-2017-earnings-supn/1699268.html.

SUPN has been the subject of several other research reports. BidaskClub downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and set a $51.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. Cowen and Company set a $50.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Janney Montgomery Scott restated a “hold” rating and set a $47.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Finally, B. Riley restated a “buy” rating and set a $50.00 target price (down previously from $53.00) on shares of Supernus Pharmaceuticals in a research note on Monday, November 6th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $49.60.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at $37.25 on Monday. The stock has a market capitalization of $1,909.51, a PE ratio of 35.14, a PEG ratio of 1.58 and a beta of 1.30. Supernus Pharmaceuticals has a 52 week low of $20.33 and a 52 week high of $50.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.74 and a current ratio of 1.82.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares of the company’s stock, valued at approximately $623,250. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the completion of the transaction, the vice president now directly owns 17,500 shares of the company’s stock, valued at approximately $791,525. The disclosure for this sale can be found here. In the last ninety days, insiders sold 153,709 shares of company stock valued at $7,223,108. Insiders own 6.70% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. raised its holdings in Supernus Pharmaceuticals by 3,455.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after acquiring an additional 2,315 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC raised its holdings in Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 1,462 shares in the last quarter. Advisor Group Inc. raised its holdings in Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after acquiring an additional 410 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Supernus Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after acquiring an additional 517 shares in the last quarter. 96.11% of the stock is owned by hedge funds and other institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.